drugset / Trial / NCT01063933

Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

NCT01063933

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purposes of this study are to evaluate the pharmacokinetics (affect the body has on a drug), and pharmacodynamics (affect the drug has on the body) and safety of an experimental intravenous (within a vein) flu medication, peramivir, in children. Participants will include 63 hospitalized children with confirmed flu. Children will be grouped according to age and younger children will not receive drug until safety data from the groups of older children are reviewed. Hospitalized children may receive up to 5 doses of peramivir. Study procedures include: nasal/throat swabs, reporting any experienced side effects, physical examination including assessment of the nervous system, and blood sample collection. Participants will be involved in study related procedures for up to 28 days.

Timeline

Start
Primary completion
2011-08
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PERAMIVIR ANHYDROUS Small molecule 10 mg/kg Intravenous
Subject PERAMIVIR ANHYDROUS Small molecule 12 mg/kg Intravenous
Subject PERAMIVIR ANHYDROUS Small molecule 14 mg/kg Intravenous
Subject PERAMIVIR ANHYDROUS Small molecule 16 mg/kg Intravenous
Subject PERAMIVIR ANHYDROUS Small molecule 18 mg/kg Intravenous

Indications